Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Sichuan University

Status

Not yet enrolling

Conditions

Non-small Cell Lung Cancer Stage IIIB

Non-small Cell Lung Cancer Stage ⅢA

Treatments

Other: cycles of neoadjuvant therapy and duration of waiting for surgery

Study type

Observational

Funder types

Other

Identifiers

NCT06394427

2024-674

Details and patient eligibility

About

to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Enrollment

250 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed as primary lung cancer through cytology or histological examination;
- ECOG score of 0 or 1; ③ 18 years old or above;
  - Received imaging examination, with a preliminary clinical staging of stage III;
    - Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available.

Exclusion criteria

Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders;
- Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.